Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review
{{output}}
The emergence of immune checkpoint inhibitors (ICIs) has ushered in a new era of tumor immunotherapy. These agents function by specifically binding to immune checkpoints, blocking the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1... ...
